Note that there were high proportion of HER2 positive breast cancers and relatively low proportion of ER/PR positive cases because ER/PR positive patients are known to be less responsive to neoadjuvant chemotherapy and they were not given neoadjuvant chemotherapy. Here, ERBB2 is linked to breast cancer.